Atotech

Atotech Ltd. provides electroplating solutions delivering chemistry, equipment, and service for technology applications. Its solutions are used in diverse end markets such as smartphones, communication infrastructure, big data infrastructure, automotive and automotive electronics. The company operates through two business segments: Electronics and General Metal Finishing. The Electronic segment supplies chemistry, production equipment and comprehensive services to the electronics industry, printed circuit board manufacturers, package substrate makers and semiconductor companies. The General Metal Finishing segment supplies chemistry, production technology and comprehensive services to the surface finishing industries. Atotech was founded on December 12, 2018 and is headquartered in West Bromwich, the United Kingdom.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BERLIN, March 09, 2021 (GLOBE NEWSWIRE) -- Atotech (NYSE: ATC), a leading specialty chemicals technology company and a market leader in advanced electroplating solutions, announced today that its recently completed production site in Yangzhou, China, is now fully operational. The facility is Atotech's second chemistry plant in China. The addition of the Yangzhou facility will provide additional capacity to serve the large and growing Electronics and General Metal Finishing markets in China, and also creates important redundancy with the company's largest chemistry production site in Guangzhou.

Atotech's new production site in Yangzhou, China, comes online

BERLIN, March 04, 2021 (GLOBE NEWSWIRE) -- Atotech (NYSE: ATC), a leading specialty chemicals technology company and a market leader in advanced electroplating solutions, today reported its financial results for the fourth quarter and full year 2020 and provided guidance for full year 2021. Total organic chemistry revenue growth, a key performance indicator for the company, increased 5% over the fourth quarter of 2019. Organic chemistry revenue growth reflects chemistry revenue growth excluding the impact of foreign exchange translation (“FX”) and palladium pass-through (“palladium”).

Atotech Reports Fourth Quarter and Full Year 2020 Results and Provides 2021 Full Year Guidance

BERLIN, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Atotech (NYSE: ATC), a leading specialty chemicals technology company and a market leader in advanced electroplating solutions, closed its initial public offering of 29,268,000 shares of common stock at $17.00 per share. The gross proceeds to Atotech from the offering were approximately $497.6 million, before deducting the underwriting discount and offering expenses.

Atotech Announces Closing of Its Initial Public Offering

Angion Biomedica

Bolt Biotherapeutics

Immunocore Holdings

Landos Biopharma

Lucira Health

ON24

Pharvaris B.V.

Sana Biotechnology

Sensei Biotherapeutics

Terns Pharmaceuticals

TELUS International (Cda)

Vor Biopharma

The IPO market had its busiest week yet this year with 14 IPOs raising $3.9 billion and 27 SPACs raising $9.2 billion. German chemicals group Atotech downsized and priced below the range to raise $498 million at a $3.3 billion market cap.

U.S. IPO Weekly Recap: Biotechs Flood The IPO Market In A 14 IPO Week

Atotech is the former surface finishing business of Total, acquired by Carlyle a while ago. The company has gone public, yet investors do not like leverage and relatively modest topline sales growth despite the promise of growth markets.

Atotech: Interesting, Yet Some Doubts

Three biotechs—Sana Biotechnology, Landos Biopharma, Sensei Biotherapeutics—and chemicals specialist Atotech made their public-market debut Thursday. Here's how they fared.

A Busy Day for Biotech IPOs

Atotech Limited (NYSE: ATC) has priced 29.268 million shares at $17 per share in its downsized initial public offering (IPO), downsized from the previous 34.146 million shares at $19 and $22 per share planned earlier.

Atotech Prices Downsized IPO At $17, Carlyle Group Associates Offload Partial Stake

BERLIN, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Atotech Limited (“Atotech”), a leading specialty chemicals technology company and a market leader in advanced electroplating solutions, has priced its initial public offering of 29,268,000 of its common shares at $17.00 per share. The shares are expected to begin trading on Thursday, February 4, 2021 on the New York Stock Exchange under the ticker symbol “ATC,” and the offering is expected to close on February 8, 2021, subject to customary closing conditions. The underwriters of the offering will also have a 30-day option to purchase up to an additional 4,390,200 common shares from certain affiliates of The Carlyle Group Inc. (the “selling shareholders”).

Atotech Prices Initial Public Offering

News for Atotech Stock (ATC)